Literature DB >> 18283202

Emergence of multidrug-resistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men.

Binh An Diep1, Henry F Chambers, Christopher J Graber, John D Szumowski, Loren G Miller, Linda L Han, Jason H Chen, Felice Lin, Jessica Lin, Tiffany HaiVan Phan, Heather A Carleton, Linda K McDougal, Fred C Tenover, Daniel E Cohen, Kenneth H Mayer, George F Sensabaugh, Françoise Perdreau-Remington.   

Abstract

BACKGROUND: Infection with multidrug-resistant, community-associated, methicillin-resistant Staphylococcus aureus (MRSA) has been reported but seems to be isolated.
OBJECTIVE: To determine the incidence of a multidrug-resistant MRSA clone (USA300) in San Francisco, and to determine risk factors for the infection.
DESIGN: Population-based survey and cross-sectional study using chart review.
SETTING: 9 hospitals in San Francisco (population-based survey) and 2 outpatient clinics in San Francisco and Boston (cross-sectional study). PATIENTS: Persons with culture-proven MRSA infections in 2004 to 2006. MEASUREMENTS: Annual incidence, spatial clustering, and risk factors for multidrug-resistant USA300 infection. Pulsed-field gel electrophoresis, polymerase chain reaction assays, and DNA sequencing were used to characterize MRSA isolates.
RESULTS: The overall incidence of multidrug-resistant USA300 infection in San Francisco was 26 cases per 100,000 persons (95% CI, 16 to 36 cases per 100,000 persons); the incidence was higher in 8 contiguous ZIP codes with a higher proportion of male same-sex couples. Male-male sex was a risk factor for multidrug-resistant USA300 infection (relative risk, 13.2 [CI, 1.7 to 101.6]; P < 0.001) independent of past MRSA infection (relative risk, 2.1 [CI, 1.2 to 3.7]; P = 0.007) or clindamycin use (relative risk, 2.1 [1.2 to 3.6]; P = 0.007). The risk seemed to be independent of HIV infection. In San Francisco, multidrug-resistant USA300 manifested most often as infection of the buttocks, genitals, or perineum. In Boston, the infection was recovered exclusively from men who had sex with men. LIMITATIONS: The study was retrospective, and sexual risk behavior was not assessed.
CONCLUSION: Infection with multidrug-resistant USA300 MRSA is common among men who have sex with men, and multidrug-resistant MRSA infection might be sexually transmitted in this population. Further research is needed to determine whether existing efforts to control epidemics of other sexually transmitted infections can control spread of community-associated, multidrug-resistant MRSA.

Entities:  

Mesh:

Year:  2008        PMID: 18283202     DOI: 10.7326/0003-4819-148-4-200802190-00204

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  146 in total

Review 1.  Colonization, pathogenicity, host susceptibility, and therapeutics for Staphylococcus aureus: what is the clinical relevance?

Authors:  Steven Y C Tong; Luke F Chen; Vance G Fowler
Journal:  Semin Immunopathol       Date:  2011-12-11       Impact factor: 9.623

2.  Subinhibitory concentrations of protein synthesis-inhibiting antibiotics promote increased expression of the agr virulence regulator and production of phenol-soluble modulin cytolysins in community-associated methicillin-resistant Staphylococcus aureus.

Authors:  Hwang-Soo Joo; June L Chan; Gordon Y C Cheung; Michael Otto
Journal:  Antimicrob Agents Chemother       Date:  2010-08-16       Impact factor: 5.191

Review 3.  Novel targeted immunotherapy approaches for staphylococcal infection.

Authors:  Michael Otto
Journal:  Expert Opin Biol Ther       Date:  2010-07       Impact factor: 4.388

4.  Identification and characterization of the multidrug resistance gene cfr in a Panton-Valentine leukocidin-positive sequence type 8 methicillin-resistant Staphylococcus aureus IVa (USA300) isolate.

Authors:  Anna C Shore; Orla M Brennan; Ralf Ehricht; Stefan Monecke; Stefan Schwarz; Peter Slickers; David C Coleman
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

5.  High prevalence of colonization with Staphylococcus aureus clone USA300 at multiple body sites among sexually transmitted disease clinic patients: an unrecognized reservoir.

Authors:  Benjamin A Miko; Anne-Catrin Uhlemann; Amanda Gelman; Caroline J Lee; Cory A Hafer; Sean B Sullivan; Qiuhu Shi; Maureen Miller; Jonathan Zenilman; Franklin D Lowy
Journal:  Microbes Infect       Date:  2012-06-21       Impact factor: 2.700

6.  Genomic Epidemiology of USA300 Methicillin-Resistant Staphylococcus aureus in an Urban Community.

Authors:  Kyle J Popovich; Evan Snitkin; Stefan J Green; Alla Aroutcheva; Mary K Hayden; Bala Hota; Robert A Weinstein
Journal:  Clin Infect Dis       Date:  2015-09-07       Impact factor: 9.079

7.  Genotypic and phenotypic characteristics of Methicillin-resistant Staphylococcus aureus (MRSA) strains, isolated on three different geography locations.

Authors:  Maja Ostojić; Mirsada Hukić
Journal:  Bosn J Basic Med Sci       Date:  2015-08-04       Impact factor: 3.363

8.  Identification and Discrimination of Methicillin Resistant Staphylococcus aureus Strains Isolated from Burn Wound Sites Using PCR and Authentication with MALDI-TOF-MS.

Authors:  E Madhava Charyulu; Arumugam Gnanamani; A B Mandal
Journal:  Indian J Microbiol       Date:  2012-01-14       Impact factor: 2.461

9.  Community-associated methicillin-resistant Staphylococcus aureus colonization burden in HIV-infected patients.

Authors:  Kyle J Popovich; Bala Hota; Alla Aroutcheva; Lisa Kurien; Janki Patel; Rosie Lyles-Banks; Amanda E Grasso; Andrej Spec; Kathleen G Beavis; Mary K Hayden; Robert A Weinstein
Journal:  Clin Infect Dis       Date:  2013-01-16       Impact factor: 9.079

10.  Short communication: methicillin-resistant Staphylococcus aureus infections in children and young adults infected with HIV.

Authors:  Ashok Srinivasan; Steven Seifried; Liang Zhu; Wally Bitar; Deo K Srivastava; Jerry L Shenep; Matthew J Bankowski; Patricia M Flynn; Randall T Hayden
Journal:  AIDS Res Hum Retroviruses       Date:  2009-12       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.